Applied DNA Sciences announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC, has submitted a validation package to the New York State Department of Health in support of approval for a pharmacogenomics assay as a NYSDOH laboratory-developed test. If approved by NYSDOH, the LDT test will be used by ADCL to power its population-scale PGx testing services. "PGx testing is a logical first step into the promising field of personalized medicine that brings together ADCL’s demonstrated capacity for population-scale testing and PGx’s proven benefits to the individual. When applied to large populations, we believe that the combination will generate significant healthcare cost reductions for enterprises and overall wellness benefits to employees," stated Dr. James A. Hayward, president and CEO of Applied DNA Sciences.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APDN:
